Table 1.
Hypoglycemic effects of SXF on type 2 diabetic patients
| Patients | Average FBG (mg/dL) | % FBG decline with SXFa | ||
|---|---|---|---|---|
|
|
|
|||
| Age (years) | Sex | Before SXF | After SXF | |
| 44 | M | ~260 | 90–100 | ~63 |
| 75 | F | ~200 | 110–130 | ~40 |
| 25 | F | 150–180 | 110–120 | ~30 |
| 37 | M | 180–200 | 120–140 | ~32 |
| 41 | M | ~210 | 100–110 | ~50 |
| 64 | F | ~220 | 130–150 | ~37 |
| 53 | F | 170–190 | 100–110 | ~42 |
Note:
a
As all patients were under oral medication therapy, their average FBG levels before SXF were with medications while those after SXF were with both medications and SXF. Hence, the percent of FBG decline with SXF reflects the improved glycemic control with SXF.
Abbreviations: F, female; FBG, fasting blood glucose; M, male; SXF, SX-fraction.